MechGen Technology Platform

For MoMed Biotech, we have long been committed to original technological innovation through target protein mechanism research plus artificial intelligence. The independently developed MechGen multi-dimensional AI drug design platform can significantly shorten the new drug R&D cycle, improve the success rate of AI-driven drug design, and address the industry pain points of traditional drug development: long cycles, high costs and low success rates. Over the past year, the platform has undergone several key upgrades, and multiple R&D pipelines have achieved milestone progress.

Being selected into the Zhejiang Seed Unicorn TOP100 for two consecutive years not only represents continuous recognition of MoMed Biotech’s technological innovation capabilities, but also further consolidates the company’s leading position in AI drug discovery and precision medicine. This honor also confirms the vibrant innovation ecosystem of Hangzhou as a hub for life and health, as well as the enormous commercial value of the crossover field of “AI + biotechnology”.